ASP2767 for Glaucoma

This trial tests a new gene therapy, ASP2767, to treat open-angle glaucoma, a condition that can damage eye nerves and lead to vision loss. The researchers aim to determine if this treatment can slow or prevent further vision loss by protecting these nerves. Participants will receive a single injection of ASP2767 in one eye, and the study will assess its safety and effectiveness. Individuals with moderate to advanced open-angle glaucoma and stable vision tests might be suitable for this trial. As a Phase 1, Phase 2 trial, this research focuses on understanding how ASP2767 works in people and measuring its effectiveness in an initial, smaller group.

Research has shown that ASP2767 is being tested for safety and effectiveness in treating open-angle glaucoma. This study marks the first use of ASP2767 in humans, so information about its safety remains limited. The study monitors how participants handle varying doses of ASP2767, starting with small amounts and gradually increasing them to identify the safest dose.

ASP2767 employs a safe virus to deliver genes into the eye, a method known as gene therapy, aiming to protect the eye's nerves and slow vision loss. Although the safety of ASP2767 is still under investigation, similar treatments involving eye injections have generally been considered safe. Known risks, such as temporary increases in eye pressure, can be managed with proper care.

Researchers are excited about ASP2767 for glaucoma because it introduces a novel approach with its unique delivery method. Unlike standard treatments like eye drops or oral medications, ASP2767 is administered directly into the eye via intravitreal injection. This method allows for more targeted action, potentially improving the drug's effectiveness and reducing systemic side effects. Additionally, ASP2767 is being tested in various dosages, which could help tailor treatments to individual patient needs more precisely. This innovative approach has the potential to offer a new level of care for those managing glaucoma.

ASP2767 is a new gene therapy that early research suggests might help protect the optic nerve in people with open-angle glaucoma. This trial will explore different dosing strategies of ASP2767, including dose escalation and dose expansion phases, to assess its safety and effectiveness. The therapy uses a safe virus to deliver specific genes to the eye, which help produce proteins that could slow or stop vision loss. Studies on similar gene therapies have shown promising results in preserving sight by protecting nerve cells in the eye. ASP2767 has also received FDA Fast Track Designation, highlighting its potential to meet unmet needs in glaucoma treatment. Although researchers are testing ASP2767 in humans for the first time, the method it uses has shown promise in other studies.¹³⁵⁶⁷